BIIB earnings analysis
What we found in BIIB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Biogen delivered Q2 revenue of $2.736B, up 3.4% YoY and 10.3% sequentially, aided by Apellis, rare-disease launches, and growing anti-CD20 and LEQEMBI-related revenue. However, GAAP EPS declined to $0.66 from $4.33 a year ago and operating margin compressed to 5.5%, as Apellis-related inventory step-up, integration, R&D, SG&A and milestone costs outpaced revenue growth. The acquisition strengthens the growth portfolio but reduced liquidity to $1.285B and lifted borrowings to $8.090B, while generic-driven MS erosion remains the central operational headwind.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue returned to growth
- Q2 revenue rose $90.5M, or 3.4% YoY, to $2.736B; it was also up $256M, or 10.3%, from Q1 2026 revenue of $2.480B. Product revenue increased 2.0% to $1.916B.
- Rare disease growth remained strong
- Rare-disease revenue grew $58.7M, or 10.8%, to $601.7M. SKYCLARYS increased $37.6M to $167.9M, QALSODY rose $11.9M to $31.9M, and U.S. SPINRAZA increased $55.0M to $204.3M.
- Apellis added a new revenue stream
- The Apellis acquisition added $127.8M of specialized-immunology revenue after closing May 14, 2026, comprising $97.4M of SYFOVRE and $30.4M of EMPAVELI U.S. revenue.
- Collaboration revenue grew
- Anti-CD20 revenue increased $46.2M, or 9.9%, to $513.5M, including OCREVUS royalties of $381.4M, up from $353.8M. Alzheimer's collaboration revenue rose 16.0% to $63.7M.
- Cash generation improved year over year
- Six-month operating cash flow was $1.094B, up $674.2M, or 160.4%, from $420.2M a year earlier. Q2 free cash flow was $408M, versus $144M in Q2 2025.
- Management sees growth-product momentum
- Management expects rare-disease growth in 2026 from SKYCLARYS launches in Europe and other international markets, QALSODY's European launch, and continued U.S. ZURZUVAE patient growth.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Acquisition and launch costs compressed earnings
- GAAP diluted EPS fell $3.67, or 84.8% YoY, to $0.66, while operating margin fell to 5.5% from 30.0% in Q2 2025. Total cost and expense increased $702.1M, or 36.9%, to $2.604B.
- Legacy MS franchise continues to erode
- MS revenue declined $143.9M, or 13.0%, to $963.3M, led by a $102.7M, or 53.0%, decline in TECFIDERA to $90.9M amid generic competition. Management expects total MS revenue to decline in 2026.
- Apellis deal materially raised leverage
- Cash, cash equivalents and marketable securities fell $2.963B, or 69.7%, to $1.285B, while total borrowings increased $1.804B, or 28.7%, to $8.090B following the $5.3B Apellis acquisition.
- Working-capital cushion narrowed
- Current working capital declined $2.236B, or 39.8%, to $3.389B. Current debt increased by $800.0M and accounts receivable increased by $543.2M following the Apellis acquisition.
- New pharmaceutical tariff exposure
- Management cites a new 100% U.S. tariff on certain imported patented pharmaceuticals, biologics and ingredients, effective July 31, 2026 for certain categories and September 29, 2026 for others. It does not expect currently applicable tariffs to be material in 2026, but states additional tariffs could affect future results.
- Business-development commitments remain sizable
- Biogen could make up to $7.9B in future third-party milestones, including approximately $1.0B development, $0.9B regulatory and $6.0B commercial milestones. RayThera also carries a proposed $225.0M upfront payment plus up to $775.0M in milestones.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.66
- Gross margin
- 71.6%
- Operating margin
- 5.5%
- Segment
- Multiple Sclerosis: $963.3M, down $143.9M (13.0%) YoY
- Segment
- Rare Disease: $601.7M, up $58.7M (10.8%) YoY
- Segment
- Specialized Immunology: $127.8M, including SYFOVRE $97.4M and EMPAVELI $30.4M
- Segment
- Biosimilars: $152.8M, down $28.9M (15.9%) YoY
- Segment
- Other product revenue: $70.8M, up $24.0M (51.3%) YoY
- Segment
- Anti-CD20 programs: $513.5M, up $46.2M (9.9%) YoY
- Segment
- Alzheimer's collaboration: $63.7M, up $8.8M (16.0%) YoY
What they said about what is next.
The 10-Q does not provide a numeric revenue or EPS outlook. Management expects 2026 MS revenue to decline, rare-disease revenue growth, relatively flat global SPINRAZA revenue, growth in U.S. ZURZUVAE revenue, and higher core R&D, SG&A and net interest expense versus 2025.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 29, 2026
- Biogen's Q1 2026 results reflect stable performance with revenue of $2.5 billion, a 2% increase year-over-year, alongside a significant earnings rebound with GAAP diluted EPS of $2.15, marking a 31% increase from the…
- 10-K · February 12, 2025
- Biogen positions itself as a neurology-, specialized immunology- and rare-disease-focused biopharma, emphasizing growth via pipeline development, collaborations (Eisai, Sage, UCB) and acquisitions. The company reported…
- 10-Q · October 30, 2024
- Biogen reported total revenue of $2,465.8 million for the three months ended September 30, 2024, with operating income recovering to $451.0 million and diluted EPS of $2.66, reversing a prior-year loss. Management…
- 10-Q · August 1, 2024
- Biogen reported Q2 revenue of $2,464.9 million, essentially flat year-over-year (up $8.9 million vs. $2,456.0 million in Q2 2023). Gross margin remained strong at ~77.9% and operating margin was ~28.3%; diluted EPS was…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BIIB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever